Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Innovation and Technology Commission, Hong Kong | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are:
Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation?
Researchers will compare people taking the Lingzhi supplement to those who don't take anything (waitlist group) to see if it works.
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | Participants receive CP003 capsules (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period. |
|
| Waitlist group | No Intervention | Participants initially wait for 6 weeks after randomization without intervention. After the waiting period, they receive the same CP003 supplement regimen (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LingZhi capsule | Drug | Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract |
| Measure | Description | Time Frame |
|---|---|---|
| Mean difference in Chalder Fatigue Score | From baseline to 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mean difference in Chalder Fatigue Score | From baseline to 12 weeks | |
| Mean difference in 36-Item Short-Form Health Survey | from baseline to 6 week and 12 week | |
| Measure | Description | Time Frame |
|---|---|---|
| Change in serum markers | for inflammation, immunity and oxidative aging | From baseline to 6 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| TUNG LEONG FONG | Contact | +852 5660 4020 | tlfong@hku.hk | |
| Guang Chen | Contact | +852 3917 6515 | gchen91@hku.hk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, The University of Hong Kong | Hong Kong | Hong Kong |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41558017 | Derived | Xun Y, Fong TL, Chen G, Feng Y, Chan L, Wang N. Effectiveness and Safety of a Supplement Containing a Pharmacologically Active Basidiomycete Mushroom for Chronic Fatigue and Post-COVID-19 Fatigue Syndrome: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2026 Jan 20;15:e82633. doi: 10.2196/82633. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015673 | Fatigue Syndrome, Chronic |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D004679 | Encephalomyelitis |
| D000090862 | Neuroinflammatory Diseases |
Not provided
Not provided
Participants are randomly assigned in a 1:1 ratio to either the intervention group or the waitlist group. The intervention group receives CP003 capsules (5 capsules once daily) for 6 weeks. The waitlist group undergoes a 6-week waiting period without any treatment.
Not provided
Not provided
Not provided
Not provided
|
| Mean difference in Fatigue Severity Score |
| from baseline to 6 week and 12 week |
| mean difference in (PROMIS) Short Form Fatigue 7A survey | from baseline to 6 week and 12 week |
| Mean difference in hospital anxiety and depression scale | from baseline to 6 week and 12 week |
| Mean difference in Pittsburgh sleep quality index | from baseline to 6 week and 12 week visit. |
| D009422 | Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |